Fluctuation analysis of lung function as a predictor of long-term response to beta2-agonists.
The response to beta(2)-agonists differs between asthmatics and has been linked to subsequent adverse events, even death. Possible determinants include beta(2)-adrenoceptor genotype at position 16, lung function and airway hyperresponsiveness. Fluctuation analysis provides a simple parameter alpha measuring the complex correlation properties of day-to-day peak expiratory flow. The present study investigated whether alpha predicts clinical response to beta(2)-agonist treatment, taking into account other conventional predictors. Analysis was performed on previously published twice-daily peak expiratory flow measurements in 66 asthmatic adults over three 6-month randomised order treatment periods: placebo, salbutamol and salmeterol. Multiple linear regression was used to determine the association between alpha during the placebo period and response to treatment (change in the number of days with symptoms), taking into account other predictors namely beta(2)-adrenoceptor genotype, lung function and its variability, and airway hyperresponsiveness. The current authors found that alpha measured during the placebo period considerably improved the prediction of response to salmeterol treatment, taking into account genotype, lung function or its variability, or airway hyperresponsiveness. The present study provides further evidence that response to beta(2)-agonists is related to the time correlation properties of lung function in asthma. The current authors conclude that fluctuation analysis of lung function offers a novel predictor to identify patients who may respond well or poorly to treatment.
Thamrin
C
C
Division of Paediatric Respiratory Medicine, Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland. cindy.thamrin@insel.ch
Stern
G
G
Strippoli
M-P F
MP
Kuehni
C E
CE
Suki
B
B
Taylor
D R
DR
Frey
U
U
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D008168:Lung / Q000378:metabolism*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D015272:Pulmonary Medicine / Q000379:methods; D012044:Regression Analysis; D000068299:Salmeterol Xinafoate; D013997:Time Factors; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol